Gsk Share Discussion Threads

[abdullla] 12/10/2022 16:03

Yes Pierre i am not immune,maybe i have'nt a shoulder to cry on .

[pierre oreilly] 12/10/2022 15:51

Abdull, I would think all investors are down loads - are you saying you aren't?

Almost everyone in the uk is down a lot too, only they won't realise it until they cash in their pension/remortgage/try to sell their house.

The only people up are those with luck beyond belief, and a few hundred bankers up billions by either causing or deepening the crisis.

They probably sold in unison everything they had power over at a relatively high pound, and at some stage, they'll buy it all back with low value pounds. Billions upon billions at very little personal risk. Billions into their pockets from those building a pension or otherwise have the city/wall st managing their cash (probably unknowingly).

Not to worry, been through 3 crashes now - it always bounces back and goes higher.

[alibizzle] 12/10/2022 15:30

Yes Abdulla it could be worse but I have no other shares and all my.money with GSK stock

[netcurtains] 12/10/2022 13:56

blimey Addullla how do you know this sort of stuff...

Will it finish the day BLUE or RED?

[abdullla] 12/10/2022 11:03

What about investors here sitting on a quarter of a million pounds paper losses,by the way GSK up 25p this morning will shortly be zero up .

[tradermichael] 12/10/2022 11:02

Ali, I don't think you are alone in that boat!

[alibizzle] 12/10/2022 09:24

As my shares in haleon and GSK have dropped in value by over 14k I need GSK to get back to around £18 or haleon to rise to around £5 , both seem unlikely so will sit on them for as long as it takes

[tradermichael] 12/10/2022 08:51

And this time last year, $1.40 = £1, now, £1.10 = £1

[patientcapital] 12/10/2022 08:38

Over 40% of earnings in a strong currency.

[charlie9038] 12/10/2022 08:37

Great time to add
gla

[netcurtains] 12/10/2022 08:36

Interesting

[tradermichael] 11/10/2022 07:41

And this year it's on Wednesday 2 November. Expect outstanding performance!

[berny3] 11/10/2022 07:28

27th October 2021 was when 3rd quarter results came out last year

[ridingthewaves1] 10/10/2022 19:32

When is next news expected here

[blackhorse23] 10/10/2022 09:25

RENE (LSE) produced ground breaking data , excellent

[tradermichael] 09/10/2022 17:45

Alp - yes, a good point. And these advanced antibody treatments potentially bring strong opportunities to extend to other therapies.

[alphorn] 09/10/2022 09:53

TM - To add to your post about late stage trials it should be noted that they can be used to increase potential patient exposure for later marketing (Phase IIIb trials) and Phase IV trials to explore more indications......... etc.

[tradermichael] 09/10/2022 09:04

The third phase of clinical trials typically lasts between one and four years. FDA Approval: Once Phase 3 has concluded, the company studying the drug can submit a New Drug Application (NDA) or a biologics license application (BLA) for the treatment to the Food and Drug Administration (FDA).

Finally, on Phase 4, after a product receives FDA approval and is on the market for consumers to use, further clinical trials may continue to gather more information on side effects, risks, benefits, and best uses. These studies are known as post-marketing surveillance (PMS) trials.

Phase 4 trials usually include hundreds to a few thousand participants.

[netcurtains] 08/10/2022 19:06

How many phases are normally after phase 3?
And how long has average phase 3 take?

Cheers Net.

[alphorn] 08/10/2022 18:33

'safety and tolerability profile' I would hope so - but does it work? That is the question.

[tradermichael] 08/10/2022 18:11

This is all you need to know:

GSK PLC on Wednesday said its drug for metastatic non-squamous non-small cell lung cancer Jemperli, or dostarlimab, is advancing to a phase 3 trial following positive results.

Jemperli is an antibody approved for the treatment of endometrial cancer in the US and EU.

Non-squamous means flat cells do not look like a fish scale under a microscope.

Citing its phase 2 Perla study, the Brentford, west London-based pharmaceuticals firm said that the safety and tolerability profile of dostarlimab was consistent with previous clinical trials of similar regimens.

Further, in its Costar phase 2/3 trial, now advancing to phase 3, GSK stated that the trial met its pre-specified expansion criteria per protocol.

"These trials support the ambition for dostarlimab to become the backbone of our ongoing immuno-oncology-based research and development programme when used alone and in combination with standard of care and future novel cancer therapies, particularly in patients with currently limited treatment options," said Hesham Abdullah, Senior Vice President & Global Head of GSK's Oncology Development arm.

[paul planet earth] 08/10/2022 16:40

'Forced Recession'..whats that all about!

[pol123] 08/10/2022 12:16

Forced recession in the US, works well for big Pharma for obvious reasons, strong dollar, resilient earnings I could go on. Makes GSK one of the best plays around IMO. I have recently stated we will be back to £15+ over the next 6 months. One caveat being Russia going nuclear

[tradermichael] 07/10/2022 11:49

Its entirely probable, given third quarter 2022 results on Wednesday 2 November.

These are expected to show a strong performance, especially with the strong dollar vs the weak pound.